Wells David R. 4
4 · ENDRA Life Sciences Inc. · Filed Jun 10, 2020
Insider Transaction Report
Form 4
Wells David R.
Chief Financial Officer
Transactions
- Conversion
Common Stock
2020-06-08$0.87/sh+10,350$9,005→ 110,003 total - Conversion
Series A Convertible Preferred Stock
2020-06-08$1143.68/sh−8.744$10,000→ 0 totalExercise: $0.87From: 2019-12-11→ Common Stock (10,350 underlying)
Holdings
- 24,786(indirect: By StoryCorp Consulting)
Common Stock
Footnotes (3)
- [F1]Includes unvested restricted stock units.
- [F2]The Series A Convertible Preferred Stock has a face value of $1,000 per share and accrues dividends thereon at an annual rate of 6.0%. The face value plus accrued and unpaid dividends of the Series A Convertible Preferred Stock is convertible into common stock at a price per share of $0.87.
- [F3]The Series A Convertible Preferred Stock has no expiration date.